Actively Recruiting
Using Blood-Based Liquid Biopsy to Improve Low-Dose CT Lung Cancer Screening in High-Risk Adults Aged 21 to 75
Led by National University Hospital, Singapore · Updated on 2026-01-22
140
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Lung cancer is a leading cause of cancer deaths, often diagnosed late. This research investigates a blood-based liquid biopsy test used before low-dose CT LDCT scans to identify high-risk individuals unlikely to have lung cancer. The goal is to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, especially for high-risk groups including never-smokers with a family history of lung cancer. The study involves three groups high-risk individuals without lung cancer, patients with early-stage lung cancer, and patients with advanced-stage lung cancer. High-risk participants receive two blood tests a DNA methylation-based assay SPOT-MAS and an exosome-based assay, followed by an LDCT scan. If the blood test is positive but LDCT is negative, a CT-PET scan is offered. Early and advanced lung cancer patients provide blood samples for assay evaluation. Some participants may have additional follow-up tests depending on results. Participants will undergo blood collection, LDCT scans, and possibly CT-PET or other imaging tests. Researchers will measure how well the liquid biopsy tests predict lung cancer absence, the number of people who might avoid LDCT scans, and test accuracy compared to imaging. Cost-effectiveness and safety will also be assessed. The study lasts up to 12 months, monitoring participants closely throughout.
CONDITIONS
Brief Title
Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here